Incyte (INCY) PT Raised to $98 at Argus on Jakafi Sales and Takeover Potential

September 26, 2016 7:21 AM EDT
Get Alerts INCY Hot Sheet
Price: $102.02 +2.09%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade INCY Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Argus reiterated a Buy rating and raised its price target on Incyte (NASDAQ: INCY) to $98.00 (from $92.00) based on higher-than-expected 2Q16 sales and EPS and increased company guidance for Jakafi sales in 2016.

In addition, they believe Incyte could be a takeover candidate given the recent uptick in healthcare M&A and selloff in biotech stocks, perhaps from Gilead (NASDAQ: GILD) who may want to boost its oncology pipeline.

The firm is raising 2016 EPS estimate to $0.45 from $0.32. They are also raising 2017 estimate to $1.33 from $1.31. Additionally, they are maintaining their revenue forecast at $1.0 billion for 2016 and raising their forecast to $1.4 billion from $1.3 billion for 2017.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $88.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Rumors

Related Entities

Argus

Add Your Comment